Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABAL.L Regulatory News (ABAL)

  • There is currently no data for ABAL

Trading Update

7 Feb 2013 14:25

RNS Number : 4127X
Imaginatik PLC
07 February 2013
Β 

ο»Ώ

7 February 2013

Β 

Imaginatik Plc

("Imaginatik" or the "Company")

Β 

Trading Update

Β 

Imaginatik plc (AIM: IMTK.L), the world's first full service innovation provider offeringΒ a range of technology products and consultancy, today announces an update on trading for the year ending 31 March 2013.

Β 

While good progress has been made this year on signing new customers and up-selling to existing customers, three long-standing customers which were expected to renew in the second half of the year have opted not to do so, due to budgetary constraints. These three contracts were expected to generate licence fee income of approximately Β£0.35m to be recognized in the results for the current financial year.

Β 

Each of these contracts was based on the Company's old 'technology only' model with no consultancy support, a model which Imaginatik is making efforts to move away from in order to increase both the effectiveness of the innovation programmes and the stickiness of the customer base.

Β 

In addition to the loss of these contracts, there remains some uncertainty over the timing of the signatures on some potential new contracts. The timing of contract signatures may impact the level of loss for the year and the Company's working capital requirements.

Β 

Therefore, the Board believes both revenues and operating losses are likely to be below market expectations.

Β 

In light of the above, the Company is considering the possibility of seeking shareholder approval of the cancellation of trading in the Company shares on AIM ("Admission"). The Directors of the Company consider that the costs associated with maintaining Admission may not be currently justified by the benefits given the low liquidity in the Company's shares and the current difficulties in sourcing equity financing for smaller companies in the public markets. A further announcement will be made in due course.

Β 

Matt Cooper, Executive Chairman of Imaginatik, commented: "The number of new blue-chip companies turning to Imaginatik as their innovation partner of choice is a fantastic endorsement of our business. However, our return to revenue growth and profitability has not been as swift as we would hope. We do however continue to firmly believe the long-term prospects for the Company to be significant. The Board will now commence a review as to whether maintaining the AIM listing is in the best interests of the Company's shareholders."

Β 

Β 

For further information please contact:

Β 

Imaginatik plc

Tel: 020 7917 2975

Matt Cooper, Executive Chairman / Shawn Taylor, CFO

Northland Capital Partners Limited

Tel: 020 7796 8800

Edward Hutton / William Vandyk

Newgate Threadneedle

Tel: 020 7653 9850

Caroline Evans-Jones / Hilary Millar

Β 

About Imaginatik

Β 

Imaginatik provides a range of Innovation solutions comprised of consultancy, enterprise software and program management to deliver innovation results to companies such as The World Bank, The Chubb Group of Insurance Companies, State Farm, Exxon Mobil, Pfizer, Goodyear, Paccar and Cargill. Few companies possess the internal capability to consistently generate fresh ideas, identify those worth pursuing and reliably transform them into real, value-enhancing assets. Imaginatik's mission is to help these companies build sustainable innovation competencies.

Imaginatik is a public company whose shares are traded on the AIM market of the London Stock Exchange (LSE:IMTK.L) and is a World Economic Forum Technology Pioneer with offices in Boston, MA, and Winchester, UK. For more information visitΒ www.imaginatik.com.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTUGUPPPUPWGCM
Date   Source Headline
27th Nov 20137:00 amRNSHalf Yearly Report
24th Oct 20137:00 amRNSContract Win
10th Oct 201310:01 amRNSHolding(s) in Company
2nd Oct 20137:00 amRNSIssue of Equity
1st Oct 201310:03 amRNSTransaction in Own Shares/Director's Dealing
23rd Sep 20137:00 amRNSContract Win with Shell
18th Sep 20132:03 pmRNSResult of AGM
27th Aug 20131:50 pmRNSNotice of AGM
24th Jul 20137:00 amRNSFinal Results
8th Jul 20137:00 amRNSContract Win
1st Jul 20137:00 amRNSChange of Adviser
21st Jun 20137:00 amRNSBoard Changes
13th Jun 20137:00 amRNSConsultancy Update
31st May 20137:00 amRNSTotal Voting Rights
16th May 20131:03 pmRNSHolding(s) in Company
16th May 20137:00 amRNSHolding(s) in Company
13th May 201312:16 pmRNSResult of General Meeting
26th Apr 20134:52 pmRNSPublication of Circular
26th Apr 20137:00 amRNSProposed Placing
16th Apr 201312:20 pmRNSCapital Market Strategy Update
7th Feb 20132:25 pmRNSTrading Update
10th Dec 20127:00 amRNSContract Wins
22nd Nov 20127:00 amRNSShare Options
21st Nov 20127:00 amRNSHalf Yearly Report
25th Oct 20127:00 amRNSTrading Update
2nd Oct 20127:00 amRNSLitigation Conclusion
14th Sep 20121:02 pmRNSResult of AGM
14th Sep 20127:00 amRNSAGM Statement
23rd Aug 20127:00 amRNSNotice of AGM
4th Jul 201212:04 pmRNSHolding(s) in Company
2nd Jul 20122:22 pmRNSHolding(s) in Company
29th Jun 20123:30 pmRNSHolding(s) in Company
29th Jun 201212:12 pmRNSHolding(s) in Company
28th Jun 20121:36 pmRNSHolding(s) in Company
27th Jun 201211:20 amRNSResult of General Meeting
20th Jun 20121:41 pmRNSDirectorate Change
11th Jun 20128:30 amRNSDirector/PDMR Shareholding
11th Jun 20128:00 amRNSProposed Placing
11th Jun 20128:00 amRNSFinal Results
17th Apr 20127:00 amRNSTrading Update
17th Apr 20127:00 amRNSContract Wins
29th Feb 20127:00 amRNSContract with US Healthcare Services Provider
21st Feb 20121:45 pmRNSHolding(s) in Company
20th Feb 201212:54 pmRNSHolding(s) in Company
15th Feb 201212:16 pmRNSHolding(s) in Company
15th Feb 20127:00 amRNSShare Option Schemes
8th Feb 20127:00 amRNSIssue of Equity
3rd Feb 201211:39 amRNSHolding(s) in Company
2nd Feb 201210:49 amRNSHolding(s) in Company
30th Jan 20127:00 amRNSSenior Management Appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.